Redirection of the Immune Response to the Functional Catalytic Domain of the Cystein Proteinase Cruzipain Improves Protective Immunity against Trypanosoma cruzi Infection

被引:40
作者
Cazorla, Silvia I. [1 ,2 ,3 ]
Frank, Fernanda M. [1 ,2 ,3 ]
Becker, Pablo D. [6 ]
Arnaiz, Maria [4 ]
Mirkin, Gerardo A. [3 ]
Corral, Ricardo S. [5 ]
Guzman, Carlos A. [6 ]
Malchiodi, Emilio L. [1 ,2 ,3 ]
机构
[1] Univ Buenos Aires, Catedra Inmunol, RA-1113 Buenos Aires, DF, Argentina
[2] Univ Buenos Aires, Inst Estudios Inmunidad Humoral IDEHU, CONICET UBA, Fac Farm & Bioquim, RA-1113 Buenos Aires, DF, Argentina
[3] Univ Buenos Aires, Dept Microbiol Parasitol & Inmunol, Fac Med, RA-1113 Buenos Aires, DF, Argentina
[4] ANLIS Malbran, Inst Nacl Parasitol Dr Mario Fatala Chaben, Buenos Aires, DF, Argentina
[5] Hosp Ninos Dr Ricardo Gutierrez, Serv Parasitol Chagas, Buenos Aires, DF, Argentina
[6] Helmholtz Ctr Infect Res, Dept Vaccinol & Appl Microbiol, D-38124 Braunschweig, Germany
关键词
SUSCEPTIBLE MOUSE STRAIN; T-CELL RESPONSES; ANTIGEN; INTERLEUKIN-10; VACCINATION; IL-10; IMMUNIZATION; REACTIVITY; EPITOPES; PROTEASE;
D O I
10.1086/652872
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Despite the strong immune responses elicited after natural infection with Trypanosoma cruzi or vaccination against it, parasite survival suggests that these responses are insufficient or inherently inadequate. T. cruzi contains a major cystein proteinase, cruzipain, which has a catalytic N-terminal domain and a C-terminal extension. Immunizations that employed recombinant cruzipain or its N- and C-terminal domains allowed evaluation of the ability of cruzipain to circumvent responses against the catalytic domain. This phenomenon is not a property of the parasite but of cruzipain itself, because recombinant cruzipain triggers a response similar to that of cruzipain during natural or experimental infection. Cruzipain is not the only antigen with a highly immunogenic region of unknown function that somehow protects an essential domain for parasite survival. However, our studies show that this can be reverted by using the N- terminal domain as a tailored immunogen able to redirect host responses to provide enhanced protection.
引用
收藏
页码:136 / 144
页数:9
相关论文
共 43 条
[1]   IDENTIFICATION OF A TRYPANOSOMA-CRUZI ANTIGEN THAT IS SHED DURING THE ACUTE PHASE OF CHAGAS-DISEASE [J].
AFFRANCHINO, JL ;
IBANEZ, CF ;
LUQUETTI, AO ;
RASSI, A ;
REYES, MB ;
MACINA, RA ;
ASLUND, L ;
PETTERSSON, U ;
FRASCH, ACC .
MOLECULAR AND BIOCHEMICAL PARASITOLOGY, 1989, 34 (03) :221-228
[2]   CD8+-T-cell-dependent control of Trypanosoma cruzi infection in a highly susceptible mouse strain after immunization with recombinant proteins based on amastigote surface protein 2 [J].
Araújo, AFS ;
de Alencar, BCG ;
Vasconcelos, JRC ;
Hiyane, MI ;
Marinho, CRF ;
Penido, MLO ;
Boscardin, SB ;
Hoft, DF ;
Gazzinelli, RT ;
Rodrigues, MM .
INFECTION AND IMMUNITY, 2005, 73 (09) :6017-6025
[3]  
ARNHOLDT ACV, 1993, J IMMUNOL, V151, P3171
[4]  
BEN YCA, 1988, T R SOC TROP MED HYG, V82, P77
[5]   Proteolytic cleavage of chemokines by Trypanosoma cruzi's cruzipain inhibits chemokine functions by promoting the generation of antagonists [J].
Benitez-Hernandez, I. ;
Mendez-Enriquez, E. ;
Ostoa, P. ;
Fortoul, T. ;
Ramirez, J. A. ;
Stempin, C. ;
Cerban, F. ;
Soldevila, G. ;
Garcia-Zeped, E. A. .
IMMUNOBIOLOGY, 2010, 215 (05) :413-426
[6]   Specific cleavage sites on human IgG subclasses by cruzipain, the major cysteine proteinase from Trypanosoma cruzi [J].
Berasain, P ;
Carmona, C ;
Frangione, B ;
Cazzulo, JJ ;
Goñi, F .
MOLECULAR AND BIOCHEMICAL PARASITOLOGY, 2003, 130 (01) :23-29
[7]   Current status and future prospects for a vaccine against American trypanosomiasis [J].
Bhatia, Vandanajay ;
Garg, Nisha .
EXPERT REVIEW OF VACCINES, 2005, 4 (06) :867-880
[8]   Peptide-based analysis of the amino acid sequence important to the immunoregulatory function of Trypanosoma cruzi Tc52 virulence factor [J].
Borges, M ;
Da Silva, AC ;
Sereno, D ;
Ouaissi, A .
IMMUNOLOGY, 2003, 109 (01) :147-155
[9]   Prime-boost immunization with cruzipain co-administered with MALP-2 triggers a protective immune response able to decrease parasite burden and tissue injury in an experimental Tryponosoma cruzi infection model [J].
Cazorla, Silvia I. ;
Frank, Fernanda M. ;
Becker, Pablo D. ;
Corral, Ricardo S. ;
Guzman, Carlos A. ;
Malchiodi, Emilio L. .
VACCINE, 2008, 26 (16) :1999-2009
[10]   Oral vaccination with Salmonella enterica as a cruzipain-DNA delivery system confers protective immunity against trypanosoma cruzi [J].
Cazorla, Silvia I. ;
Becker, Pablo D. ;
Frank, Fernanda M. ;
Ebensen, Thomas ;
Sartori, Maria J. ;
Corral, Ricardo S. ;
Malchiodi, Emilio L. ;
Guzman, Carlos A. .
INFECTION AND IMMUNITY, 2008, 76 (01) :324-333